(VIANEWS) – Shares of Viking Therapeutics (NASDAQ: VKTX) fell by a staggering 21.84% in 10 sessions from $11.64 at 2023-03-20, to $9.10 at 12:45 EST on Monday, after four consecutive sessions in a row of losses. NASDAQ is falling 0.68% to $11,743.22, after five consecutive sessions in a row of gains.
Viking Therapeutics’s last close was $8.85, 26.13% under its 52-week high of $11.98.
About Viking Therapeutics
Viking Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the development of novel therapies for metabolic and endocrine disorders. The company's lead drug candidate is VK2809, an orally available tissue and receptor-subtype selective agonist of the thyroid hormone receptor beta (TRß), which is in Phase IIb clinical trials to treat patients with biopsy-confirmed non-alcoholic steatohepatitis, as well as NAFLD. It also develops VK5211, an orally available non-steroidal selective androgen receptor modulator that is in Phase II clinical trials for the treatment of patients recovering from non-elective hip fracture surgery; VK0612, an orally available Phase IIb-ready drug candidate for type 2 diabetes; and VK0214, an orally available tissue and receptor-subtype selective agonist of the TRß for X-linked adrenoleukodystrophy. The company was incorporated in 2012 and is headquartered in San Diego, California.
Earnings Per Share
As for profitability, Viking Therapeutics has a trailing twelve months EPS of $-0.6.
The company’s return on equity, which measures the profitability of a business relative to shareholder’s equity, for the twelve trailing months is negative -39.67%.
Yearly Top and Bottom Value
Viking Therapeutics’s stock is valued at $9.10 at 12:45 EST, way below its 52-week high of $11.98 and way higher than its 52-week low of $2.02.
Volatility
Viking Therapeutics’s last week, last month’s, and last quarter’s current intraday variation average was a negative 7.43%, a negative 1.34%, and a positive 3.49%.
Viking Therapeutics’s highest amplitude of average volatility was 8.61% (last week), 4.18% (last month), and 3.49% (last quarter).
Moving Average
Viking Therapeutics’s worth is way under its 50-day moving average of $10.13 and way higher than its 200-day moving average of $5.48.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, Viking Therapeutics’s stock is considered to be overbought (>=80).
More news about Viking Therapeutics (VKTX).
